Clinical trial
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With…
NCT00439647 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00439647 |
|---|---|
| Title | Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis |
| Official title | A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Male Osteoporosis |
| Intervention type | Drug |
| Interventions | Zoledronic acid 5 mg iv, Placebo |
| Enrollment | 1,199 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Feb 23, 2007 |
| Last update posted | Apr 21, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Czechia, Denmark, Finland, Germany, Hungary, Iceland, Italy and 11 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: